Steve Bunk | Feb 1, 1999 | 5 min read
After years of clinical studies in Germany, St. John's wort (Hypericum perforatum) is poised to undergo scientific scrutiny in the United States as a treatment for depression. Never clinically tested in this country, the yellow-blossomed, roadside weed, native to much of America's Northwest and to many other parts of the world, is now the focus of four such trials. Perhaps foremost among them is a $4.3 million study funded by the Office of Alternative Medicine (OAM) in the National Institutes